CR8224A - Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor - Google Patents

Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor

Info

Publication number
CR8224A
CR8224A CR8224A CR8224A CR8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A
Authority
CR
Costa Rica
Prior art keywords
crystal
polipeptices
necrosis factor
tumor necrosis
factor receptor
Prior art date
Application number
CR8224A
Other languages
English (en)
Inventor
Osslund Timothy
L Clogston Christi
Lee Crampton Shon
B Bass Randal
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR8224A publication Critical patent/CR8224A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion suministra formas cristalinas de los polipeptidos TNFR2, que incluyen los polipeptidos TNFR2:Fc y el etanercept cristalino. Una modalidad de la invencion es un cristal de etanercept; en ciertas modalidades el cristal de etanercept esta en la forma de una barra, y /o tiene una longitud maxima de entre 0.5 milimetros y 1.5 milimetros de entre 0.05 milimetros y 0.3 milimetros.
CR8224A 2003-08-01 2006-02-01 Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor CR8224A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49182703P 2003-08-01 2003-08-01

Publications (1)

Publication Number Publication Date
CR8224A true CR8224A (es) 2006-07-18

Family

ID=34115556

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8224A CR8224A (es) 2003-08-01 2006-02-01 Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor

Country Status (19)

Country Link
US (1) US7276477B2 (es)
EP (1) EP1654281A1 (es)
JP (1) JP2007521315A (es)
KR (1) KR20070008501A (es)
CN (1) CN100509847C (es)
AU (1) AU2004262014B2 (es)
BR (1) BRPI0413197A (es)
CA (1) CA2533796A1 (es)
CR (1) CR8224A (es)
EC (1) ECSP066299A (es)
HK (1) HK1093749A1 (es)
IL (1) IL173413A0 (es)
NO (1) NO20060128L (es)
NZ (1) NZ545221A (es)
RU (1) RU2006101216A (es)
SG (1) SG145712A1 (es)
TW (1) TWI291468B (es)
WO (1) WO2005012353A1 (es)
ZA (1) ZA200600909B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
US20090232808A1 (en) * 2005-01-28 2009-09-17 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
CN1954882A (zh) * 2005-10-14 2007-05-02 李海 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途
CA2629323A1 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
CN101360724A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 盐形式
WO2007062337A2 (en) * 2005-11-18 2007-05-31 Astrazeneca Ab Crystalline forms
US20090069292A1 (en) * 2005-11-18 2009-03-12 Astrazeneca Ab Liquid Formulations
CN101360725B (zh) * 2005-11-18 2011-09-21 阿斯利康公司 固体制剂
WO2007100937A2 (en) * 2006-01-19 2007-09-07 The Regents Of The University Of Michigan System and method for spectroscopic photoacoustic tomography
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
WO2008063639A2 (en) * 2006-11-21 2008-05-29 Massachusetts Eye And Ear Infirmary Compositions and methods for preserving cells of the eye
US20080123083A1 (en) * 2006-11-29 2008-05-29 The Regents Of The University Of Michigan System and Method for Photoacoustic Guided Diffuse Optical Imaging
WO2009018429A2 (en) * 2007-07-31 2009-02-05 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healt Of Human Services, National Institutes Of Healt TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
AU2009210741A1 (en) * 2008-02-07 2009-08-13 Amgen Inc. Stabilized protein compositions
CN101591388A (zh) * 2008-05-30 2009-12-02 上海复旦张江生物医药股份有限公司 一种可溶性tnf受体突变体
TR201903546T4 (tr) 2009-07-28 2019-04-22 Ge Healthcare Bio Sciences Corp Aşı stabilizatörü.
CN109157742B (zh) 2009-08-03 2022-04-05 因卡伯实验室有限责任公司 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法
EP2494352B1 (en) * 2009-10-26 2020-04-08 Prometheus Biosciences, Inc. Assays for the detection of anti-tnf drugs and autoantibodies
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
US8721620B2 (en) 2009-12-24 2014-05-13 Rani Therapeutics, Llc Swallowable drug delivery device and methods of drug delivery
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
SG189391A1 (en) 2010-10-18 2013-05-31 Nestec Sa Methods for determining anti-drug antibody isotypes
US8809271B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402807B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9259386B2 (en) 2010-12-23 2016-02-16 Rani Therapeutics, Llc Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9861683B2 (en) 2010-12-23 2018-01-09 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8734429B2 (en) 2010-12-23 2014-05-27 Rani Therapeutics, Llc Device, system and methods for the oral delivery of therapeutic compounds
US9415004B2 (en) 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US10639272B2 (en) 2010-12-23 2020-05-05 Rani Therapeutics, Llc Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device
US8846040B2 (en) 2010-12-23 2014-09-30 Rani Therapeutics, Llc Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9629799B2 (en) 2010-12-23 2017-04-25 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9283179B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9402806B2 (en) 2010-12-23 2016-08-02 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8980822B2 (en) 2010-12-23 2015-03-17 Rani Therapeutics, Llc Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US9284367B2 (en) 2010-12-23 2016-03-15 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8809269B2 (en) 2010-12-23 2014-08-19 Rani Therapeutics, Llc Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8969293B2 (en) 2010-12-23 2015-03-03 Rani Therapeutics, Llc Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20130330340A1 (en) * 2011-02-25 2013-12-12 Stephen R. Hamilton Production of n- and o-sialylated tnfrii-fc fusion protein in yeast
AU2012244764B2 (en) * 2011-04-20 2016-10-13 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
EA026226B1 (ru) * 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104661651A (zh) * 2012-07-09 2015-05-27 科荣生生物科学公司 表现出不溶性微粒显著减少的依那西普制剂
ES2657377T3 (es) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept plegado correctamente con alta pureza y excelente rendimiento
KR20150093695A (ko) 2012-11-09 2015-08-18 코넬 유니버시티 Malt1의 소분자 억제제
WO2014078627A1 (en) 2012-11-19 2014-05-22 Merck Sharp & Dohme Corp. Liquid formulations for tnfr:fc fusion proteins
CN104870019A (zh) * 2012-11-27 2015-08-26 阿特根公司 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物
CA2930227C (en) * 2013-11-29 2021-09-28 Ares Trading S.A. A liquid formulation of a fusion protein comprising tnfr and fc region
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US10080877B2 (en) 2014-07-25 2018-09-25 Warsaw Orthopedic, Inc. Drug delivery device and methods having a drug cartridge
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
EP3017825A1 (en) * 2014-11-06 2016-05-11 Ludwig-Maximilians-Universität München An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same
TW201628644A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
EP3227683B1 (en) 2014-12-05 2019-04-24 Nestec S.A. Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
CA2971186A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
EP3236990B1 (en) 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
CN105636937B (zh) * 2015-01-27 2018-07-17 深圳华大生命科学研究院 用于保存生物样品的稳定剂
EP3265107B1 (en) 2015-03-02 2024-10-02 180 Therapeutics LP Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
USD802757S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
CN109963590B (zh) 2016-09-02 2024-03-15 加利福尼亚大学董事会 涉及白介素-6受体α结合单链可变片段的方法和组合物
EP3518971A4 (en) * 2016-09-28 2020-05-13 Board Of Regents, The University Of Texas System ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF
KR20180046888A (ko) 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
WO2020003139A2 (en) * 2018-06-26 2020-01-02 Lupin Limited Stable lyophilized dosage form of protein
CN112805014A (zh) 2018-07-03 2021-05-14 芬内克制药股份有限公司 无水硫代硫酸钠的调配物
CN111408343B (zh) * 2019-01-08 2022-01-28 湖南农业大学 三维立体生物炭的制备方法及其在重金属吸附中的应用
CN110433172B (zh) * 2019-07-10 2022-04-08 郴州市第一人民医院 一种具有治疗非小细胞肺癌功效的药物及其用途
JP2024503239A (ja) 2020-12-22 2024-01-25 アムジェン インコーポレイテッド 細胞培養法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
KR100923514B1 (ko) * 2000-12-28 2009-10-27 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법

Also Published As

Publication number Publication date
TW200510453A (en) 2005-03-16
ECSP066299A (es) 2006-07-28
SG145712A1 (en) 2008-09-29
EP1654281A1 (en) 2006-05-10
NZ545221A (en) 2009-09-25
WO2005012353A1 (en) 2005-02-10
TWI291468B (en) 2007-12-21
NO20060128L (no) 2006-04-06
CN1829739A (zh) 2006-09-06
KR20070008501A (ko) 2007-01-17
CA2533796A1 (en) 2005-02-10
AU2004262014A1 (en) 2005-02-10
HK1093749A1 (en) 2007-03-09
JP2007521315A (ja) 2007-08-02
IL173413A0 (en) 2006-06-11
BRPI0413197A (pt) 2006-10-03
AU2004262014B2 (en) 2010-06-17
CN100509847C (zh) 2009-07-08
ZA200600909B (en) 2007-05-30
US7276477B2 (en) 2007-10-02
RU2006101216A (ru) 2007-07-20
US20050032183A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
CR8224A (es) Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor
ATE461217T1 (de) Glp-1-verbindungen
DK1581300T3 (da) Væskeapplikator med mekanisme til brydning af flere ampuller
ATE445402T1 (de) Neue verwendung von pde5-hemmern
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
DE502004006863D1 (de) Synthese von phenylsubstituierten fluoranthenen durch diels-alder-reaktion und ihre verwendung
ES2570772T3 (es) Dispositivos polarizantes y procedimientos de fabricación de los mismos
CY1113721T1 (el) Πολυσταθης ανακλαστικη διαταξη υγρων κρυσταλλων
DE60321906D1 (de) Management des stimulationserfolgs bei mehrkammerstimulation
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
UY28258A1 (es) Tratamiento terapeutico
NO20061122L (no) 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer
CL2009001214A1 (es) Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
DK1899334T3 (da) Naphthyridinforbindelser
CR7042A (es) Indanil aminas aciladas y su uso como farmacos
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ATE407466T1 (de) Schleifringbürste und damit ausgestattete schleifringeinheit
NO20093542L (no) Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer
ECSP088468A (es) Moduladores de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
UY29774A1 (es) Inhibidor de atm
UY28344A1 (es) Nuevos compuestos
DE60323645D1 (de) Duschvorrichtung mit bräunungsvorrichtung

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)